Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010;10(8):7404-20.
doi: 10.3390/s100807404. Epub 2010 Aug 9.

Use of sensors in the treatment and follow-up of patients with diabetes mellitus

Isabel Torres  1 , Maria G Baena, Manuel Cayon, Jose Ortego-Rojo, Manuel Aguilar-Diosdado
Affiliations
Review

Use of sensors in the treatment and follow-up of patients with diabetes mellitus

Isabel Torres et al. Sensors (Basel). 2010.

Abstract

Glucose control is the cornerstone of Diabetes Mellitus (DM) treatment. Although self-regulation using capillary glycemia (SRCG) still remains the best procedure in clinical practice, continuous glucose monitoring systems (CGM) offer the possibility of continuous and dynamic assessment of interstitial glucose concentration. CGM systems have the potential to improve glycemic control while decreasing the incidence of hypoglycemia but the efficiency, compared with SRCG, is still debated. CGM systems have the greatest potential value in patients with hypoglycemic unawareness and in controlling daily fluctuations in blood glucose. The implementation of continuous monitoring in the standard clinical setting has not yet been established but a new generation of open and close loop subcutaneous insulin infusion devices are emerging making insulin treatment and glycemic control more reliable.

Keywords: diabetes mellitus; glucose control; sensors.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Representative graph of the glucose values obtained using the GlucoDay system in a patient with Type 1 DM. Note the wide variations in glycemia values, and the nocturnal hypoglycemia.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gavin JR, Alberti KG, Davidson MB, DeFronzo RA, Drash A, Gabbe SG, Genuth S, Harris MI, Kahn R, Keen H, Knowler WC, Lebovitz H, Maclaren NK, Palmer JP, Raskin P, Rizza RA, Stern MP. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26:5–20.
    1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053. - PubMed
    1. Dyck PJ, Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, Wilson DM, O'Brien PC, Melton LJ, Service FJ. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester diabetic neuropathy study. Neurology. 1993;43:817–824. - PubMed
    1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:977–986. - PubMed
    1. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 2005;353:2643–2653. - PMC - PubMed

MeSH terms